Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Sexual Health Reports
Published in: Current Sexual Health Reports 4/2017

Open Access 01-12-2017 | Female Sexual Dysfunction and Disorders (M Chivers and C Pukall, Section Editors)

Recent Developments in Psychopharmaceutical Approaches to Treating Female Sexual Interest and Arousal Disorder

Author: Stephanie Both

Published in: Current Sexual Health Reports | Issue 4/2017

Login to get access

Abstract

Purpose of Review

This review summarizes the recent literature and empirical studies on psychopharmacological approaches to treating female sexual interest/arousal disorder (FSIAD).

Recent Findings

Several new drugs for FSIAD that are intended to increase sexual responsiveness by influencing central excitatory and inhibitory neuromodulatory processes are under development. Studies on flibanserin resulted in the first approved medication for the treatment of low sexual desire in premenopausal women. New drugs under development are testosterone combined with sildenafil or buspiron, bremelanotide, BP101, and nasal testosterone (TBS-2).

Summary

Although pharmacological enhancement of sexual responsiveness may be potentially helpful in the treatment of FSIAD, the observed effects of flibanserin and other new drugs under development seem limited in terms of clinical significance. Given the multifactorial character of FSIAD, it may be important to integrate psychopharmacological treatment with sex therapy for optimal treatment efficacy.
Literature
1.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. fifth edition ed. Arlington: American Psychiatric Association; 2013.CrossRef
2.
Baumeister RF, Catanese KR, Vohs KD. Is there a gender difference in strength of sex drive? Theoretical views, conceptual distinctions, and a review of relevant evidence. Personal Soc Psychol Rev. 2001;5:242–73.CrossRef
3.
West SL, D'Aloisio AA, Agans RP, Kalsbeek WD, Borisov NN, Thorp JM. Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women. Arch Intern Med. 2008;168(13):1441–9.CrossRefPubMed
4.
Witting K, Santtila P, Varjonen M, Jern P, Johansson A, von der PB, et al. Female sexual dysfunction, sexual distress, and compatibility with partner. J Sex Med. 2008;5(11):2587–99.CrossRefPubMed
5.
Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol. 2008;112(5):970–8.CrossRefPubMed
6.
Toates F. An integrative theoretical framework for understanding sexual motivation, arousal, and behavior. J Sex Res. 2009;46(2–3):168–93.CrossRefPubMed
7.
8.
9.
Barlow DH. Causes of sexual dysfunction: the role of anxiety and cognitive interference. J Consult Clin Psychol. 1986;54(2):140–8.CrossRefPubMed
10.
11.
12.
13.
•• Kingsberg SA, Clayton AH, Pfaus JG. The female sexual response: current models, neurobiological underpinnings and agents currently approved or under investigation for the treatment of hypoactive sexual desire disorder. CNS Drugs. 2015;29(11):915–33. Gives an extensive and detailed overview of models, neurobiological mechanisms, and approved or investigational drugs for the treatment of HSDD in women. CrossRefPubMed
14.
Volkow ND, Wang GJ, Telang F, Fowler JS, Logan J, Childress AR, et al. Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. J Neurosci. 2006;26(24):6583–8.CrossRefPubMed
15.
Oei N, Rombouts S, Soeter R, van Gerven JM, Both S. Dopamine modulates reward system activity during subconscious processing of sexual stimuli. 2011;
16.
Brom M, Both S, Laan E, Everaerd W, Spinhoven P. The role of conditioning, learning and dopamine in sexual behavior: a narrative review of animal and human studies. Neurosci Biobehav Rev. 2013;38C:38–59.
17.
Pfaus JG, Kippin TE, Centeno S. Conditioning and sexual behavior: a review. Horm Behav. 2001;40(2):291–321.CrossRefPubMed
18.
Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science. 1997;275(5306):1593–9.CrossRefPubMed
19.
Coyle E, Karatzias T, Summers A, Power M. Emotions and emotion regulation in survivors of childhood sexual abuse: the importance of “disgust” in traumatic stress and psychopathology. Eur J Psychotraumatol 2014;5.
20.
Bitzer J, Giraldi A, Pfaus J. Sexual desire and hypoactive sexual desire disorder in women. Introduction and overview. Standard operating procedure (SOP Part 1). J Sex Med. 2013;10(1):36–49.CrossRefPubMed
21.
Katz M, Derogatis LR, Ackerman R, Hedges P, Lesko L, Garcia M Jr, et al. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med. 2013;10(7):1807–15.CrossRefPubMed
22.
Derogatis LR, Komer L, Katz M, Moreau M, Kimura T, Garcia M Jr, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET study. J Sex Med. 2012;9(4):1074–85.CrossRefPubMed
23.
Thorp J, Simon J, Dattani D, Taylor L, Kimura T, Garcia M Jr, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med. 2012;9(3):793–804.CrossRefPubMed
24.
•• Jaspers L, Feys F, Bramer WM, Franco OH, Leusink P, Laan. Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: a systematic review and meta-analysis. JAMA Intern Med. 2016;176(4):453–62. A critical systematic review and meta-analysis of published and unpublished randomized clinical trials assessing efficacy and safety of flibanserin for the treatment of HSDD in women. CrossRefPubMed
25.
26.
Bancroft J, Graham CA, Janssen E, Sanders SA. The dual control model: current status and future directions. J Sex Res. 2009;46(2):121–42.CrossRefPubMed
27.
• Bloemers J, van Rooij K, Poels S, Goldstein I, Everaerd W, Koppeschaar H, et al. Toward personalized sexual medicine (part 1): integrating the “dual control model” into differential drug treatments for hypoactive sexual desire disorder and female sexual arousal disorder. J Sex Med. 2013;10(3):791–809. Decribes the development of drug treatments for HSDD from a theoretical perspective, more specifically the dual control model of sexual response. CrossRefPubMed
28.
van der Made F, Bloemers J, Yassem WE, Kleiverda G, Everaerd W, van Ham D, et al. The influence of testosterone combined with a PDE5-inhibitor on cognitive, affective, and physiological sexual functioning in women suffering from sexual dysfunction. J Sex Med. 2009;6(3):777–90.CrossRefPubMed
29.
van Rooij K, Poels S, Bloemers J, Goldstein I, Gerritsen J, van Ham D, et al. Toward personalized sexual medicine (part 3): testosterone combined with a serotonin1A receptor agonist increases sexual satisfaction in women with HSDD and FSAD, and dysfunctional activation of sexual inhibitory mechanisms. J Sex Med. 2013;10(3):824–37.CrossRefPubMed
30.
Poels S, Bloemers J, van Rooij K, Goldstein I, Gerritsen J, van Ham D, et al. Toward personalized sexual medicine (part 2): testosterone combined with a PDE5 inhibitor increases sexual satisfaction in women with HSDD and FSAD, and a low sensitive system for sexual cues. J Sex Med. 2013;10(3):810–23.CrossRefPubMed
31.
Pfaus J, Giuliano F, Gelez H. Bremelanotide: an overview of preclinical CNS effects on female sexual function. J Sex Med. 2007;4(Suppl 4):269–79.CrossRefPubMed
32.
Clayton AH, Althof SE, Kingsberg S, Derogatis LR, Kroll R, Goldstein I, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016;12(3):325–37.
33.
Gorsel H, Laan, Tkachenko NM, Dickstein J, Kreppner W. Pharmacokinetics and pharmacodynamic efficacy of testosterone intranasal gel in women with hypoactive sexual desire disorder and anorgasmia. J Sex Med. 2012;9(3):162–80.
34.
Laan E, Nievaart M, Tkachenko NM, Dickstein J, Kreppner W, Lunsen RHW. Randomized, placebo controlled, five-arm parallel group study to assess efficacy of TBS-2 intranasal gel using vibrotactile stimulation combined with visual sexual stimulation in women with anorgasmia. J Sex Med. 2013;10:165–6.CrossRef
35.
Andreev-Andrievskiy A, Lomonosov M, Popova A, Lagereva E, Clement P, Salimov R, et al. BP101 peptide promotes female sexual receptivity in the rat. J Sex Med. 2017;14(3):336–46.CrossRefPubMed
36.
Mataix-Cols D, DLC F, Monzani B, Rosenfield D, Andersson E, Perez-Vigil A, et al. D-cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders: a systematic review and meta-analysis of individual participant data. JAMA Psychiatry. 2017;74(5):501–10.CrossRefPubMed
37.
Botreau F, Paolone G, Stewart J. D-cycloserine facilitates extinction of a cocaine-induced conditioned place preference. Behav Brain Res. 2006;172(1):173–8.CrossRefPubMed
38.
Paolone G, Botreau F, Stewart J. The facilitative effects of D-cycloserine on extinction of a cocaine-induced conditioned place preference can be long lasting and resistant to reinstatement. Psychopharmacology. 2009;202(1–3):403–9.CrossRefPubMed
39.
• Brom M, Laan E, Everaerd W, Spinhoven P, Trimbos B, Both S. D-cycloserine reduces context specificity of sexual extinction learning. Neurobiol Learn Mem. 2015;125:202–10. The first study that showed facilitating effects of d-cycloserine, a learning enhancing drug, on sexual associative learning. CrossRefPubMed
40.
Both S, Weijmar Schultz WC, Laan E. Treating women’s sexual desire and arousal problems. In: Peterson ZD, editor. The Wiley handbook of sex therapy. Sussex: John Wiley & Sons; 2017. p. 11–31.
41.
• Conaglen HM, Conaglen JV. Integrating sexual partners into pharmacological sex therapy. In: Peterson ZD, editor. The Wiley handbook of sex therapy. Sussex: John Wiley & Sons; 2017. p. 453–67. Describes the importance and ways to integrate pharmacological treatment of sexual dysfunction with sex therapy for the couple. CrossRef
Metadata
Title
Recent Developments in Psychopharmaceutical Approaches to Treating Female Sexual Interest and Arousal Disorder
Author
Stephanie Both
Publication date
01-12-2017
Publisher
Springer US
Published in
Current Sexual Health Reports / Issue 4/2017
Print ISSN: 1548-3584
Electronic ISSN: 1548-3592
DOI
https://doi.org/10.1007/s11930-017-0124-3

Other articles of this Issue 4/2017

Current Sexual Health Reports 4/2017 Go to the issue

Preclinical and Psychophysiology (F Guarraci and L Marson, Section Editors)

The Role of Ovarian Hormones and the Medial Amygdala in Sexual Motivation

Male and Female Surgical Interventions (A Burnett and C Carson, Section Editors)

Prosthetic Considerations in Neophallic Reconstruction

Male and Female Surgical Interventions (A Burnett and C Carson, Section Editors)

Surgical Management of the Concealed Penis in Adults

Female Sexual Dysfunction and Disorders (M Chivers and C Pukall, Section Editors)

Brain Imaging of Human Sexual Response: Recent Developments and Future Directions

Medical Comorbidities (M Miner, S Parish and A Goldstein, Section Editors)

The Testosterone Trials: What the Results Mean for Healthcare Providers and for Science

Preclinical and Psychophysiology (F Guarraci and L Marson, Section Editors)

Sexual Transmission of Cyst-Forming Coccidian Parasites with Complex Life Cycles